Table 2 Characteristics of patients before bone marrow cell application
All patients (n = 62) | Limb salvage and wound healing (n = 33) | Major limb amputation or nonhealing ulcer (n = 22) | p valuea | |
|---|---|---|---|---|
Age (years) | 64 ± 11 | 60 ± 11 | 66 ± 9 | 0.03 |
Sex (females) | 8 (13 %) | 4 (12 %) | 4 (18 %) | 0.53 |
Mode of administration (IM) | 32 (52 %) | 18 (55 %) | 11 (50 %) | 0.74 |
Diabetes mellitus | 41 (66 %) | 21 (64 %) | 15 (68 %) | 0.73 |
Arterial hypertension | 48 (77 %) | 22 (67 %) | 19 (86 %) | 0.10 |
Hyperlipidemia | 32 (52 %) | 18 (55 %) | 12 (55 %) | 1.0 |
Obesity (BMI > 30) | 12 (19 %) | 8 (24 %) | 3 (14 %) | 0.34 |
Smoking | 25 (40 %) | 16 (48 %) | 7 (32 %) | 0.22 |
Soluble creatinine (μmol/l) | 95 ± 47 | 90 ± 40 | 91 ± 20 | 0.91 |
CRP (mg/l) | 25 ± 51 | 11 ± 18 | 48 ± 77 | 0.04 |
Leu (109/l) | 9.1 ± 4.7 | 8.8 ± 5.2 | 9.4 ± 4.2 | 0.64 |
Rutherford category 6b | 5.1 ± 0.3 | 0 (0 %) | 5 (23 %) | 0.02 |
ABI | 0.8 ± 0.4 | 0.8 ± 0.3 | 0.7 ± 0.5 | 0.70 |
tcpO2 baseline (mmHg) | 14 ± 10 | 16 ± 10 | 9 ± 8 | 0.005 |
Pain scale (0–10) | 4.7 ± 2.4 | 4.1 ± 2.5 | 5.7 ± 1.5 | 0.004 |
Fibrinogen (g/l) | 3.9 ± 0.9 | 3.7 ± 0.9 | 4.1 ± 0.9 | 0.10 |
Cholesterol (mmol/l) | 4.3 ± 1.1 | 4.4 ± 1.1 | 4.3 ± 0.9 | 0.78 |
Atorvastatin (mg) | 17 ± 13 | 18 ± 10 | 15 ± 17 | 0.40 |
BM-MNCs (109) | 4.2 ± 1.4 | 4.5 ± 1.4 | 3.8 ± 1.2 | 0.03 |
CD34+ (106) | 28 ± 16 | 34 ± 19 | 20 ± 10 | 0.001 |
Thromboangiitis obliterans | 6 (10 %) | 6 (18 %) | 0 | 0.03 |